Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Semaglutide With Metformin vs. Metformin Alone in Obese PCOS
NCT06896981Phase 3Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in polycystic ovary syndrome (PCOS), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Weight at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06896981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896981.